Terns Pharmaceuticals, Inc. Current Ratio

Current Ratio of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Ratio growth rates and interactive chart. The current ratio is a liquidity ratio that measures whether a firm has enough resources to meet its short-term obligations. It is calculated as current assets divided by current liabilities. A ratio below 1 indicates potential trouble for a company, as it doesn't have enough current assets to pay for its short-term liabilities. A ratio above 2 is usually considered healthy.


Highlights and Quick Summary

  • Current Ratio for the quarter ending March 31, 2022 was 25.0 (a 2.13% increase compared to previous quarter)
  • Year-over-year quarterly Current Ratio decreased by -22.17%
  • Annual Current Ratio for 2021 was 24.48 (a 529.51% increase from previous year)
  • Annual Current Ratio for 2020 was 3.89 (a -13.4% decrease from previous year)
  • Annual Current Ratio for 2019 was 4.49 (a -87.95% decrease from previous year)
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Ratio of Terns Pharmaceuticals, Inc.

Most recent Current Ratioof TERN including historical data for past 10 years.

Interactive Chart of Current Ratio of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Current Ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 25.0
2021 24.48 25.94 32.12 23.64 24.48
2020 3.89 3.89
2019 4.49 4.49
2018 37.25

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.